During the corresponding time, Krystal Biotech Inc recorded a revenue increase by 24.14 % year on year, sequentially revenue grew by 2.46 %. While revenue at the Krystal Biotech Inc 's corporate clients
Krystal Biotech Inc's Comment on Sales, Marketing and Customers
The company operates in the aesthetic skin treatment market, targeting consumer segments interested in wellness, beauty, and healthy aging. It focuses on women experiencing early aging of the décolleté skin, which is thinner and more prone to aging signs. The company is developing KB304, an intradermal injectable designed to stimulate skin biorejuvenation by delivering COL3A1 and ELN transgenes to restore collagen and skin elasticity, addressing wrinkles and other signs of aging in the décolleté area. Clinical trials (PEARL-2) demonstrated positive safety and efficacy outcomes, including improvements in wrinkles, elasticity, crepiness, hydration, radiance, and increased subject satisfaction. The company plans to initiate a Phase 2 study in 2027. Additionally, it is advancing other aesthetic skin condition product candidates, including KB301, which targets structural protein loss in skin.
In a positive turn of events for the global oncology field, Krystal Biotech, a forward-thinking Carnegie Mellon spinoff focused on pioneering gene therapeutics, has announced the administration of the first dose to a patient in a Phase 1 clinical trial of their novel therapy, inhaled KB707. This trial focuses on treating patients with locally advanced or metastatic solid tumors of the lung, marking a significant milestone in their fervent efforts towards transforming oncology treatments, and indeed, the futures of countless patients across the globe.The said drug, KB707, has received Fast Track Designations for both its inhaled and intratumoral variants from the U.S. Food and Drug Administration (FDA). This ...
PITTSBURGH, Dec. 19, 2023 - Krystal Biotech Inc, a leading biotechnology company specializing in the development of genetic medicines for diseases with high unmet medical needs, has announced that it has been granted Orphan Drug Designation (ODD) by the Japan Ministry of Health, Labour and Welfare (MHLW). This designation is for their innovative treatment, beremagene geperpavec-svdt (B-VEC or VYJUVEK), aimed at addressing the debilitating condition known as dystrophic epidermolysis bullosa (DEB). Dystrophic epidermolysis bullosa is a rare genetic disorder that affects the skin and mucus membranes, causing fragile skin that is susceptible to blistering and easy damage. The disease often leads to seve...
PITTSBURGH, Nov. 27, 2023 – Krystal Biotech, Inc. (NASDAQ: KRYS), a renowned biotechnology firm specializing in the discovery, development, and commercialization of genetic medicines to address diseases with significant unmet medical needs, has announced the validation of its Marketing Authorization Application (MAA) for VYJUVEK (beremagene geperpavec-svdt, also known as B-VEC) by the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP). This significant milestone marks the entry of VYJUVEK into the regulatory review phase. Pending CHMP s opinion, anticipated in the second half of 2024, the potential marketing authorization will revolutionize the treatment of dy...
Krystal Biotech Inc’s Comment on Sales, Marketing and Customers
The company operates in the aesthetic skin treatment market, targeting consumer segments interested in wellness, beauty, and healthy aging. It focuses on women experiencing early aging of the décolleté skin, which is thinner and more prone to aging signs. The company is developing KB304, an intradermal injectable designed to stimulate skin biorejuvenation by delivering COL3A1 and ELN transgenes to restore collagen and skin elasticity, addressing wrinkles and other signs of aging in the décolleté area. Clinical trials (PEARL-2) demonstrated positive safety and efficacy outcomes, including improvements in wrinkles, elasticity, crepiness, hydration, radiance, and increased subject satisfaction. The company plans to initiate a Phase 2 study in 2027. Additionally, it is advancing other aesthetic skin condition product candidates, including KB301, which targets structural protein loss in skin.
Sources:
Krystal Biotech Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Krystal Biotech Inc’s corporate clients.
For your research, we’ve provided 9 tables on Krystal Biotech Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
150.24 %